EP0317278A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Proteolytic fragments and synthetic peptides that block the binding of von Willebrand factor to the platelet membrane glycoprotein Ib
Assignee: Scripps Research Institute
•
Filing: 1988-11-16
•
Granted: —
•
Expires: 2008-11-16
Abstract
Abstract Peptides which inhibit the binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices. The method of preventing platelet aggregation or thrombosis by administering one of these peptides is also disclosed.
Inventors
- 👤 Theodore S. Zimmerman
- 👤 Zaverio M. Ruggeri
- 👤 Richard A. Houghten
- 👤 Vincete Vincete
- 👤 Hiroshi Mohri
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 09:10
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A; A61; A61P; A61P7/00; A61P7/02; C07K14/46; C07K14/47; C07K14/4701; C07K14/4702; C07K14/4703; A61K; A61K38/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
44 words
A peptide of a 45 kDa amino terminal tryptic fragment of glycocalicin selected from the following amino acid sequence: which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 2
Dependent Claim
44 words
A peptide of a 45 kDa amino terminal tryptic fragment of glycocalicin selected from the following amino acid sequence: which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 3
Dependent Claim
45 words
A sequential subset of a 45 kDa amino terminal tryptic fragment of glycocalicin selected from the following amino acid sequence: which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 4
Dependent Claim
45 words
A sequential subset of a 45 kDa amino terminal tryptic fragment of glycocalicin selected from the following amino acid sequence: which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 5
Dependent Claim
45 words
A peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices selected from the group of peptides consisting of: DKRNLTALPPDLPKDTT; NLTALPPDLPKDTTI; PPDLPKDTTILHLSE; PGLLTPTPKLEKLSL; KQGVDVKAMTSNVAS; GDTDLYDYYPEEDTE; EEDTEGDKVRATRTV; PPDLPKDTT; or EEDTE.
Claim 6
Dependent Claim
45 words
A peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices selected from the group of peptides consisting of: DKRNLTALPPDLPKDTT; NLTALPPDLPKDTTI; PPDLPKDTTILHLSE; PGLLTPTPKLEKLSL; KQGVDVKAMTSNVAS; GDTDLYDYYPEEDTE; EEDTEGDKVRATRTV; PPDLPKDTT; or EEDTE.
Claim 7
Dependent Claim
17 words
A peptide which comprises,within the peptide of Claim 3,any sequential subset of amino acids and derivatives thereof.
Claim 8
Dependent Claim
45 words
A peptide having the general formula (KR) n , wherein n=2-10 and R n wherein n=2-20 and any derivatives thereof which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 9
Dependent Claim
45 words
A peptide having the general formula (KR) n , wherein n=2-10 and R n wherein n=2-20 and any derivatives thereof which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib and platelet membrane glycoprotein Ib related molecules or other cells and cell matrices.
Claim 10
Independent Claim
35 words
A method for inhibiting aggregation of platelets to each other comprising contacting the platelets with a peptide as claimed in any of claims 1-5 in an amount of said peptide effective to inhibit said aggregation.
Claim 11
Independent Claim
34 words
A method for inhibiting thrombosis in a patient which comprises administering to said patient a peptide as claimed in any of claims 1-5 in an amount of said peptide effective to inhibit said thrombosis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.